Clinical Trials Logo

Clinical Trial Summary

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of cat allergy. This study will investigate the safety of Cat-PAD administered as increasing single doses.


Clinical Trial Description

This study is designed as a two centre, randomised, placebo-controlled, escalating single dose study in up to 88 cat allergic subjects. Cohorts of 8 subjects will be enrolled. Each cohort will undergo screening 14-28 days before treatment and a baseline challenge for EPSR and LPSR to cat allergen injected into the arm 7 days before treatment. On the treatment day, subjects will be injected either intradermally (into the skin) or subcutaneously (under the skin) with a single dose of Cat-PAD or placebo and safety observations made for 8 h. After 21 days, subjects will again have cat allergen injected into the arm and the EPSR and LPSR will be recorded. The dose of Cat-PAD will be increased in successive cohorts, provided that the previous dose tested was well tolerated. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00685711
Study type Interventional
Source Circassia Limited
Contact
Status Completed
Phase Phase 1/Phase 2
Start date January 2008
Completion date July 2008

See also
  Status Clinical Trial Phase
Terminated NCT02959073 - Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients N/A
Completed NCT00987909 - Exposure Chamber Trial With Cat Immunotherapy Phase 2
Completed NCT01383603 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 2 - Gene Array Analysis Phase 1
Completed NCT01383590 - Identification of Potential Biomarkers of Peptide Immunotherapy. Part 1 - Proteomics Analysis Phase 1
Completed NCT01003301 - The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge Phase 2
Completed NCT02311413 - A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy Phase 2
Completed NCT02237196 - Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy Phase 1/Phase 2
Completed NCT02399579 - Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients N/A
Terminated NCT01292070 - Safety Evaluation of an Experimental Treatment, Intradermal Human Fcγ1-Fel d1 Fusion Protein (GFD), for Cat Allergy Phase 0
Completed NCT00867906 - Safety of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects With Controlled Asthma Phase 2
Completed NCT04435678 - Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens N/A
Completed NCT01033344 - Cat-PAD Exposure Chamber Study Phase 2
Completed NCT02040844 - Phase III Cat-PAD Follow-on Study Phase 3
Completed NCT01604018 - An Optional Two Year Follow Up Study to Study CP005A N/A
Completed NCT01272323 - Cat-PAD Follow on Study N/A
Completed NCT03838731 - Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge Phase 2
Completed NCT00729508 - Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects Phase 2
Recruiting NCT05331170 - Viral Mucosal Reprogramming Phase 2